Schwab Charles Investment Management Inc. increased its position in shares of Myriad Genetics, Inc. (NASDAQ:MYGN) by 4.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 698,450 shares of the company’s stock after buying an additional 29,348 shares during the period. Schwab Charles Investment Management Inc. owned 1.03% of Myriad Genetics worth $13,411,000 at the end of the most recent reporting period.
Other large investors also recently modified their holdings of the company. Albert D Mason Inc. increased its stake in shares of Myriad Genetics by 1.5% in the first quarter. Albert D Mason Inc. now owns 16,382 shares of the company’s stock worth $315,000 after buying an additional 250 shares during the last quarter. Commerzbank Aktiengesellschaft FI increased its stake in shares of Myriad Genetics by 1.7% in the first quarter. Commerzbank Aktiengesellschaft FI now owns 21,733 shares of the company’s stock worth $417,000 after buying an additional 357 shares during the last quarter. Creative Planning increased its stake in shares of Myriad Genetics by 11.8% in the first quarter. Creative Planning now owns 6,371 shares of the company’s stock worth $122,000 after buying an additional 671 shares during the last quarter. Foundry Partners LLC increased its stake in shares of Myriad Genetics by 3.6% in the first quarter. Foundry Partners LLC now owns 22,500 shares of the company’s stock worth $432,000 after buying an additional 775 shares during the last quarter. Finally, Credit Agricole S A increased its stake in shares of Myriad Genetics by 4.3% in the fourth quarter. Credit Agricole S A now owns 20,899 shares of the company’s stock worth $348,000 after buying an additional 869 shares during the last quarter.
Myriad Genetics, Inc. (NASDAQ MYGN) opened at 24.70 on Tuesday. The stock has a market capitalization of $1.68 billion, a PE ratio of 52.78 and a beta of 0.32. The company’s 50-day moving average price is $22.64 and its 200 day moving average price is $19.25. Myriad Genetics, Inc. has a 12 month low of $15.15 and a 12 month high of $32.54.
Myriad Genetics (NASDAQ:MYGN) last posted its quarterly earnings data on Tuesday, May 2nd. The company reported $0.27 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.24 by $0.03. The firm had revenue of $196.90 million during the quarter, compared to the consensus estimate of $188.89 million. Myriad Genetics had a return on equity of 10.53% and a net margin of 4.26%. On average, analysts forecast that Myriad Genetics, Inc. will post $1.01 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Schwab Charles Investment Management Inc. Buys 29,348 Shares of Myriad Genetics, Inc. (MYGN)” was published by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this article on another site, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this article can be accessed at https://sportsperspectives.com/2017/07/18/schwab-charles-investment-management-inc-buys-29348-shares-of-myriad-genetics-inc-mygn.html.
A number of equities research analysts recently weighed in on the company. Zacks Investment Research raised Myriad Genetics from a “hold” rating to a “buy” rating and set a $28.00 price objective on the stock in a research report on Monday. Piper Jaffray Companies reaffirmed a “hold” rating and set a $22.00 price objective on shares of Myriad Genetics in a research report on Friday. Cowen and Company reiterated a “hold” rating and issued a $25.00 price target on shares of Myriad Genetics in a research note on Friday. Jefferies Group LLC reiterated a “hold” rating and issued a $21.00 price target (up from $18.00) on shares of Myriad Genetics in a research note on Wednesday, May 3rd. Finally, BidaskClub upgraded Myriad Genetics from a “hold” rating to a “buy” rating in a research note on Saturday, June 17th. Five analysts have rated the stock with a sell rating, eight have given a hold rating and three have given a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $22.00.
Myriad Genetics Company Profile
Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.
Receive News & Ratings for Myriad Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.